About Pear Bio
Pear Bio is a company based in London (United Kingdom) founded in 2017 by Duleek Ranatunga. Pear Bio has raised $14.15 million across 3 funding rounds from investors including Merck, Octopus Ventures and Hoxton Ventures. The company has 33 employees as of December 31, 2024. Pear Bio offers products and services including Personalized Testing Services and Drug Discovery Services. Pear Bio operates in a competitive market with competitors including Newcells Biotech, InSphero, Pandorum, Vivodyne and Xilis, among others.
- Headquarter London, United Kingdom
- Employees 33 as on 31 Dec, 2024
- Founders Duleek Ranatunga
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ourotech Limited
- Date of Incorporation 29 Oct, 2019
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.15 M (USD)
in 3 rounds
-
Latest Funding Round
$14.15 M (USD), Series A
Apr 14, 2023
-
Investors
Merck
& 7 more
-
Employee Count
33
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Pear Bio
Pear Bio offers a comprehensive portfolio of products and services, including Personalized Testing Services and Drug Discovery Services.
Tests cancer treatments using 3D immune-microtumors to predict patient responses.
Identifies new targets and develops therapies for high unmet need cancers.
People of Pear Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Pear Bio
Pear Bio has successfully raised a total of $14.15M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $14.15 million completed in April 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pear Bio
Pear Bio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, Octopus Ventures and Hoxton Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investment and support for founders in technology and health sectors.
|
Locked | Locked | Locked | |
|
VC and PE firm focused on seed and early stage tech companies
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Pear Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pear Bio
Investment portfolio details for Pear Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pear Bio
Detailed financials for Pear Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pear Bio Comparisons
Peer comparison for Pear Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pear Bio
Pear Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, InSphero, Pandorum, Vivodyne and Xilis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Induced pluripotent stem cell-derived organoid models are developed for research.
|
|
| Locked | Locked | Locked |
Cell-based assays and 3D microtissues for drug screening are developed.
|
|
| Locked | Locked | Locked |
Regenerative medicine and 3D tissues are developed for therapeutic uses.
|
|
| Locked | Locked | Locked |
Developer of AI-based platform for lab-grown human tissues
|
|
| Locked | Locked | Locked |
Micro-organ sphere technologies for oncology drug discovery are developed.
|
Detailed competitors of Pear Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pear Bio
Complete news archive for Pear Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pear Bio
Pear Bio was founded in 2017.
Pear Bio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Duleek Ranatunga is the current CEO of Pear Bio. They have also founded this company.
Pear Bio is a funded company, having raised a total of $14.15M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Pear Bio is 33.
Pear Bio develops microfluidic chip for cancer drug research. The device combines tissue engineering, microfluidics, and biomaterials to represent how drugs are infused, distributed and exposed to the tumor over multiple passes during a chemo regimen. It also maps the spread of cancer using 3D imaging.
Pear Bio's top competitors include Newcells Biotech, InSphero and Vivodyne.
Pear Bio offers Personalized Testing Services and Drug Discovery Services.
Pear Bio has 8 investors. Key investors include Merck, Octopus Ventures, Hoxton Ventures, Crista Galli Ventures, and SOSV.